We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current MDNAF market cap is 129.53M. The company's latest EPS is CAD -0.1443 and P/E is -17.74.
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.73M | -8.25M | -17.4M | -22.47M | -16.3M |
| Net Income | -4.71M | -8.28M | -17.29M | -22.58M | -10.05M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 5.19M | 38M | 42.25M | 23.46M | 36.45M |
| Total Liabilities | 2.57M | 1.85M | 4.11M | 2.62M | 6.96M |
| Total Equity | 2.62M | 36.15M | 38.15M | 20.84M | 29.49M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -8.04M | -8.95M | -15.31M | -23.58M | -12.66M |
| Investing | -354k | -15M | 5.01M | 10.05M | N/A |
| Financing | 6.82M | 44.28M | 18.26M | 3.88M | 24.76M |
| Market Cap | 129.53M |
| Price to Earnings Ratio | -17.74 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.31 |
| Price to Book Ratio | 6.05 |
| Dividend Yield | - |
| Shares Outstanding | 69.64M |
| Average Volume (1 week) | 119.93k |
| Average Volume (1 Month) | 144.93k |
| 52 Week Change | 1,034.15% |
| 52 Week High | 2.10 |
| 52 Week Low | 0.158 |
| Spread (Intraday) | 0.03 (1.59%) |
| Company Name | Medicenna Therapeutics Corporation (QB) |
| Address |
200 - 1920 yonge street toronto, ontario M4S 3E2 |
| Website | https://www.medicenna.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
